Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 4.17
RVP's Cash-to-Debt is ranked higher than
63% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. RVP: 4.17 )
Ranked among companies with meaningful Cash-to-Debt only.
RVP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 5.22 Max: 24.08
Current: 4.17
0.06
24.08
Equity-to-Asset 0.71
RVP's Equity-to-Asset is ranked higher than
71% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. RVP: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
RVP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.73 Max: 0.86
Current: 0.71
0.01
0.86
Debt-to-Equity 0.13
RVP's Debt-to-Equity is ranked higher than
71% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. RVP: 0.13 )
Ranked among companies with meaningful Debt-to-Equity only.
RVP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04  Med: 0.13 Max: 62.98
Current: 0.13
0.04
62.98
Piotroski F-Score: 2
Altman Z-Score: 0.71
Beneish M-Score: -3.42
WACC vs ROIC
4.68%
-27.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -14.45
RVP's Operating Margin % is ranked lower than
71% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. RVP: -14.45 )
Ranked among companies with meaningful Operating Margin % only.
RVP' s Operating Margin % Range Over the Past 10 Years
Min: -37.83  Med: -15.57 Max: -6.25
Current: -14.45
-37.83
-6.25
Net Margin % -15.01
RVP's Net Margin % is ranked lower than
72% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. RVP: -15.01 )
Ranked among companies with meaningful Net Margin % only.
RVP' s Net Margin % Range Over the Past 10 Years
Min: -34.57  Med: -12.34 Max: 14.6
Current: -15.01
-34.57
14.6
ROE % -18.44
RVP's ROE % is ranked lower than
72% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. RVP: -18.44 )
Ranked among companies with meaningful ROE % only.
RVP' s ROE % Range Over the Past 10 Years
Min: -27.63  Med: -14.26 Max: 20.52
Current: -18.44
-27.63
20.52
ROA % -11.63
RVP's ROA % is ranked lower than
72% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. RVP: -11.63 )
Ranked among companies with meaningful ROA % only.
RVP' s ROA % Range Over the Past 10 Years
Min: -16.75  Med: -8.84 Max: 9.84
Current: -11.63
-16.75
9.84
ROC (Joel Greenblatt) % -26.93
RVP's ROC (Joel Greenblatt) % is ranked lower than
72% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. RVP: -26.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RVP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -66.55  Med: -23.48 Max: 33.35
Current: -26.93
-66.55
33.35
3-Year Revenue Growth Rate -3.80
RVP's 3-Year Revenue Growth Rate is ranked lower than
72% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. RVP: -3.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RVP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.9  Med: 1.25 Max: 15.1
Current: -3.8
-7.9
15.1
3-Year EBITDA Growth Rate -19.60
RVP's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. RVP: -19.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RVP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -71.1  Med: -28.7 Max: 285.6
Current: -19.6
-71.1
285.6
3-Year EPS without NRI Growth Rate -16.80
RVP's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. RVP: -16.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RVP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -35.6  Med: -16.8 Max: 56.5
Current: -16.8
-35.6
56.5
GuruFocus has detected 3 Warning Signs with Retractable Technologies Inc $RVP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RVP's 30-Y Financials

Financials (Next Earnings Date: 2017-11-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

RVP Guru Trades in Q3 2016

Jim Simons 54,100 sh (+19.96%)
» More
Q4 2016

RVP Guru Trades in Q4 2016

Jim Simons 69,400 sh (+28.28%)
» More
Q1 2017

RVP Guru Trades in Q1 2017

Jim Simons 91,600 sh (+31.99%)
» More
Q2 2017

RVP Guru Trades in Q2 2017

Jim Simons 109,300 sh (+19.32%)
» More
» Details

Insider Trades

Latest Guru Trades with RVP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:WAR:MMD, OTCPK:STXS, AMEX:DXR, OTCPK:REPR, OTCPK:NEPH, NAS:VLRX, NAS:BMRA, NAS:DXTR, NAS:CASM, OTCPK:UEEC, NAS:SKLN, LSE:AKR, NAS:PDEX, AMEX:ISR, OTCPK:ECIA, OTCPK:PEYE, NAS:ATEC, NAS:SSKN, NAS:NURO, OTCPK:RSCF » details
Headquarter Location:USA
Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession. It offers 1mL tuberculin; allergy antigen VanishPoint syringes; 3mL and 10mL VanishPoint syringes.

Retractable Technologies Inc was incorporated in Texas on May 9, 1994. The Company designs, develops, manufactures, and markets patented safety medical products for the healthcare industry. The Companys products with Notice of Substantial Equivalence to the U.S. Food and Drug Administration (FDA) and which are currently sold include the 1mL tuberculin; insulin; allergy antigen VanishPoint syringes; 3mL, 5mL, and 10mL VanishPoint syringes; the VanishPoint blood collection tube holder; the VanishPoint IV safety catheter; small diameter tube adapter; the Patient Safe syringe; the Patient Safe Luer Cap; and the VanishPoint Blood Collection Set. It is also selling autodisable syringes in the international market. The Companys VanishPoint safety products (consisting of 1mL tuberculin, insulin, and allergy antigen VanishPoint syringes; 0.5mL, 2ml, 3mL, 5mL, and 10mL VanishPoint syringes; VanishPoint autodisable syringe; the VanishPoint IV catheter; the VanishPoint blood collection tube holder; and the VanishPoint blood collection set. PatientSafe syringe products currently consist of 3mL, 5mL, 10mL, 20mL, 30mL, 60mL PatientSafe syringes and the PatientSafe luer cap. The PatientSafe syringe offers a patented design designed to protect patients by reducing the risk of bloodstream infections resulting from catheter hub contamination. The Company distributes its products throughout the U.S. and its territories through general line and specialty distributors. It also has trademark protection for the phrase The New Standard for Safety'. Its domestic competitors include BD and Covidien Ltd. (Covidien). Terumo Medical Corp. (Terumo), Smiths Medical, and B Braun are additional competitors with smaller market shares.

Ratios

vs
industry
vs
history
PB Ratio 0.76
RVP's PB Ratio is ranked higher than
82% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. RVP: 0.76 )
Ranked among companies with meaningful PB Ratio only.
RVP' s PB Ratio Range Over the Past 10 Years
Min: 0.27  Med: 1.14 Max: 5.62
Current: 0.76
0.27
5.62
PS Ratio 0.63
RVP's PS Ratio is ranked higher than
76% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. RVP: 0.63 )
Ranked among companies with meaningful PS Ratio only.
RVP' s PS Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.28 Max: 4.26
Current: 0.63
0.39
4.26
EV-to-EBIT -2.11
RVP's EV-to-EBIT is ranked lower than
99.99% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. RVP: -2.11 )
Ranked among companies with meaningful EV-to-EBIT only.
RVP' s EV-to-EBIT Range Over the Past 10 Years
Min: -97.9  Med: -1.7 Max: 220.8
Current: -2.11
-97.9
220.8
EV-to-EBITDA -2.55
RVP's EV-to-EBITDA is ranked lower than
99.99% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. RVP: -2.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
RVP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1714.2  Med: -2.1 Max: 23.3
Current: -2.55
-1714.2
23.3
EV-to-Revenue 0.30
RVP's EV-to-Revenue is ranked higher than
86% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.43 vs. RVP: 0.30 )
Ranked among companies with meaningful EV-to-Revenue only.
RVP' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.5  Med: 0.8 Max: 3.8
Current: 0.3
-0.5
3.8
Current Ratio 3.31
RVP's Current Ratio is ranked higher than
69% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. RVP: 3.31 )
Ranked among companies with meaningful Current Ratio only.
RVP' s Current Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.82 Max: 11.46
Current: 3.31
0.55
11.46
Quick Ratio 2.34
RVP's Quick Ratio is ranked higher than
68% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. RVP: 2.34 )
Ranked among companies with meaningful Quick Ratio only.
RVP' s Quick Ratio Range Over the Past 10 Years
Min: 0.22  Med: 2.98 Max: 10.86
Current: 2.34
0.22
10.86
Days Inventory 125.58
RVP's Days Inventory is ranked higher than
53% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. RVP: 125.58 )
Ranked among companies with meaningful Days Inventory only.
RVP' s Days Inventory Range Over the Past 10 Years
Min: 84.36  Med: 112.71 Max: 133.86
Current: 125.58
84.36
133.86
Days Sales Outstanding 41.01
RVP's Days Sales Outstanding is ranked higher than
89% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. RVP: 41.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
RVP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.16  Med: 42.75 Max: 93.15
Current: 41.01
23.16
93.15
Days Payable 77.90
RVP's Days Payable is ranked higher than
73% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. RVP: 77.90 )
Ranked among companies with meaningful Days Payable only.
RVP' s Days Payable Range Over the Past 10 Years
Min: 59.27  Med: 87.42 Max: 113.99
Current: 77.9
59.27
113.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.00
RVP's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. RVP: -3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RVP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.6  Med: -2.55 Max: -0.3
Current: -3
-14.6
-0.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.33
RVP's Price-to-Net-Cash is ranked higher than
81% of the 58 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.97 vs. RVP: 5.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RVP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.2  Med: 2.63 Max: 424.5
Current: 5.33
1.2
424.5
Price-to-Net-Current-Asset-Value 1.33
RVP's Price-to-Net-Current-Asset-Value is ranked higher than
90% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.23 vs. RVP: 1.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RVP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.81  Med: 1.92 Max: 100.33
Current: 1.33
0.81
100.33
Price-to-Tangible-Book 0.75
RVP's Price-to-Tangible-Book is ranked higher than
86% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. RVP: 0.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RVP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.45  Med: 1.38 Max: 603.85
Current: 0.75
0.45
603.85
Price-to-Intrinsic-Value-Projected-FCF 4.92
RVP's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
73% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. RVP: 4.92 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RVP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.18  Med: 1.98 Max: 154
Current: 4.92
0.18
154
Price-to-Median-PS-Value 0.50
RVP's Price-to-Median-PS-Value is ranked higher than
67% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. RVP: 0.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RVP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 2 Max: 9.24
Current: 0.5
0.43
9.24
Earnings Yield (Greenblatt) % -47.67
RVP's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. RVP: -47.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RVP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -39842.9  Med: -15.9 Max: 15871.2
Current: -47.67
-39842.9
15871.2

More Statistics

Revenue (TTM) (Mil) $30.90
EPS (TTM) $ -0.17
Beta0.38
Short Percentage of Float0.67%
52-Week Range $0.54 - 2.79
Shares Outstanding (Mil)31.67
» More Articles for RVP

Headlines

Articles On GuruFocus.com
Retractable Technologies Inc (RVP) CEO Thomas J Shaw buys 200,000 Shares Mar 16 2009 

More From Other Websites
Retractable Technologies, Inc. Files Motions in Connection with Becton, Dickinson and Co. Judgment Sep 15 2017
ETFs with exposure to Retractable Technologies, Inc. : September 14, 2017 Sep 13 2017
Retractable Technologies, Inc. :RVP-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Aug 25 2017
Retractable Technologies, Inc. Reports Sale of Common Stock Aug 24 2017
District Court Issues Final Judgment - Retractable Technologies, Inc., et. al. v. Becton, Dickinson... Aug 18 2017
Retractable Technologies posts 2Q loss Aug 14 2017
Retractable Technologies, Inc. Reports Results as of June 30, 2017 Aug 14 2017
ETFs with exposure to Retractable Technologies, Inc. : August 7, 2017 Aug 07 2017
ETFs with exposure to Retractable Technologies, Inc. : July 12, 2017 Jul 12 2017
Retractable Technologies, Inc. Declares Dividends to Series I and II Class B Convertible Preferred... Jun 30 2017
ETFs with exposure to Retractable Technologies, Inc. : June 28, 2017 Jun 28 2017
Retractable Technologies, Inc. :RVP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Jun 14 2017
Retractable Technologies, Inc. Announces Litigation Update and Results for the First Quarter of 2017 May 15 2017
ETFs with exposure to Retractable Technologies, Inc. : April 19, 2017 Apr 19 2017
Retractable Technologies, Inc. :RVP-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017 Apr 04 2017
Retractable Technologies, Inc. Reports Results for the Year 2016 Apr 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}